How reliable is ESR as a measure of disease activity in rheumatoid arthritis treated with hydroxychloroquine?
Forty-two patients with active rheumatoid arthritis treated with hydroxychloroquine sulphate (400 mg day-1) for six months have been compared with patients treated with D-penicillamine (n = 14), aurothiomalate (n = 13), sulphasalazine (n = 15) and chloroquine (n = 17) to compare the changes in articular index, plasma viscosity and ESR. Results indicate that while articular index and plasma viscosity show significant improvement for all treatments, the ESR fails to improve during hydroxychloroquine therapy.
D001172:Arthritis, Rheumatoid / Q000097:blood* / Q000188:drug therapy; D001799:Blood Sedimentation; D001809:Blood Viscosity / Q000187:drug effects; D002738:Chloroquine / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D006052:Gold Sodium Thiomalate / Q000627:therapeutic use; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use*; D008297:Male; D010396:Penicillamine / Q000627:therapeutic use; D012460:Sulfasalazine / Q000627:therapeutic use
D006052:Gold Sodium Thiomalate; D012460:Sulfasalazine; D006886:Hydroxychloroquine; D002738:Chloroquine; D010396:Penicillamine